PRISMA-combined alpha-blockers and antimuscarinics for ureteral stent-related symptoms A meta-analysis

doi:10.1097/MD.0000000000006098

CORC > 兰州大学 > 兰州大学 > 第一临床医学院 > 期刊论文

	PRISMA-combined alpha-blockers and antimuscarinics for ureteral stent-related symptoms A meta-analysis
	Zhang, YM; Chu, P; Wang, WJ; Wang, WJ (reprint author), Lanzhou Univ, Hosp 1, Dept Emergency, Lanzhou, Peoples R China.
刊名	MEDICINE
	2017-02
卷号	96 期号:7
关键词	solifenacin SRS tamsulosin terazosin tolterodine ureteric stent-related discomfort
ISSN号	0025-7974
DOI	10.1097/MD.0000000000006098
文献子类	Review
英文摘要	Background: As a monotherpay, a-blockers and anti-muscarinics are both efficacy for ureteral stent-related symptoms (SRS). The aim of the study was to systematically evaluate their efficacy of a combination therapy for SRS. Methods: Relevant studies investigating alpha-blockers and/or anti-muscarinics for SRS were identified though searching online databases including PubMed, EMBASE, Cochrane Library, and other sources up to March 2016. The RevMan software was used for data analysis, and senesitivity analysis and inverted funnel plot were also adopted. Results: Seven randomized controlled trials (RCTs) and 1 prospective controlled trial including 545 patients were selected. Compared with a-blockers, the combination group achieved significant improvements in total International Prostate Symptom Score (IPSS) [-3.93 (2.89, 4.96), P<0.00001], obstructive subscore [-1.29 (0.68, 1.89), P<0.0001], irritative subscore [-2.93 (2.18, 3.68), P<0.00001], and quality of life score [-0.99 (0.42, 1.55), P<0.001]. Compared with antimuscarinics, there were also significant differences in total IPSS [-3.49 (2.43, 4.55), P<0.00001], obstructive subscore [-1.40 (0.78, 2.01), P<0.00001], irritative subscore [-2.10 (1.30, 2.90), P<0.00001], and quality of life score [-1.18 (0.58, 1.80), P<0.001] in favor of combination group. No significant difference was found in the visual analog pain score and the urinary symptoms score in Ureteral Stent Symptom Questionnaire (USSQ). No significant difference in complications was found. Conclusions: Current analysis shows significant advantages of combination therapy compared with monotherapy of alpha-blockers or antimuscarinics alone mainly based on IPSS. More RCTs adopting validated USSQ as outcome measures are warranted to support the finding.
学科主题	General & Internal Medicine
出版地	PHILADELPHIA
语种	英语
WOS记录号	WOS:000394432800027
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/188644]
专题	第一临床医学院_期刊论文
通讯作者	Wang, WJ (reprint author), Lanzhou Univ, Hosp 1, Dept Emergency, Lanzhou, Peoples R China.
推荐引用方式 GB/T 7714	Zhang, YM,Chu, P,Wang, WJ,et al. PRISMA-combined alpha-blockers and antimuscarinics for ureteral stent-related symptoms A meta-analysis[J]. MEDICINE,2017,96(7).
APA	Zhang, YM,Chu, P,Wang, WJ,&Wang, WJ .(2017).PRISMA-combined alpha-blockers and antimuscarinics for ureteral stent-related symptoms A meta-analysis.MEDICINE,96(7).
MLA	Zhang, YM,et al."PRISMA-combined alpha-blockers and antimuscarinics for ureteral stent-related symptoms A meta-analysis".MEDICINE 96.7(2017).